PF 0713

Drug Profile

PF 0713

Alternative Names: PF0713

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Anaesthetics
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaesthesia; Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting; Sedation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaesthesia in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sedation in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for research development in Chemotherapy-induced-nausea-and-vomiting in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top